Key result
Females age <40 with BMI <20 linked to ~50% risk of prolonged or severe AEs after Comirnaty.
Why the study?
Differences between male and female genders in response to medical treatments are often neglected, and females have been observed to suffer more adverse consequences than males following COVID-19 vaccination.
Do age, sex, COVID-19 history, and BMI predict the development of adverse events following Comirnaty vaccination in healthcare workers?
Observational (n=2,385)
Do age, sex, COVID-19 history, and BMI predict the development of adverse events following Comirnaty vaccination in healthcare workers?
Young females with low BMI are at significantly higher risk for adverse events from the Comirnaty vaccine, suggesting a potential need for dose adjustment in this demographic.
Higher AE rates in females after Comirnaty; leaves open sex-specific risks pending prospective confirmation.
An important issue that is often neglected is the difference between male and female genders in response to medical treatments. In the context of COVID-19 vaccine administration, despite identical protocol strategies, it has been observed that females often suffer more adverse consequences than males. Here, we analyzed the adverse events (AEs) of the Comirnaty vaccine in a population of 2385 healthcare workers as a function of age, sex, COVID-19 history and BMI. Using logistic regression analysis, we showed that these variables may contribute to the development of AEs, particularly in young subjects, females and individuals with a BMI below 25 kg/m2. Moreover, partial dependence plots indicate a 50% probability of developing a mild AE for a long period of time (≥7 days) or a severe AE of any duration in women below 40 years old and with a BMI < 20 kg/m2. As this effect is more evident after the second dose of the vaccine, we propose to reduce the amount of vaccine for any additional booster dose in relation to age, sex and BMI. This strategy might reduce adverse events without affecting vaccine efficacy.
No takes yet. Share an insight, caveat, or question.
Azzolini et al. (2023) conducted an observational in COVID-19 vaccine adverse events (n=2,385). Comirnaty vaccine was evaluated on Adverse events (mild for ≥7 days or severe of any duration). Female sex, age <40 years, and BMI <20 kg/m2 were associated with a 50% probability of developing a mild prolonged or severe adverse event after receiving the Comirnaty vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: